Nice work. It seems concerning that there was no appreciable change in lung function in the overall CF population and no reduction in exacerbations. Does this mean the drug needs to be targeted to specific subgroups, e.g. patients with severe disease? Should we be paying for it?
What about hospitalizations?
Have you tried stratifying by genotype?
Interesting work
Nice work. It seems concerning that there was no appreciable change in lung function in the overall CF population and no reduction in exacerbations. Does this mean the drug needs to be targeted to specific subgroups, e.g. patients with severe disease? Should we be paying for it?
What about hospitalizations?
Have you tried stratifying by genotype?